NasdaqGS:ZYMEBiotechs
How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story
Zymeworks Inc. reported second-quarter 2026 results showing a net loss of US$45.02 million versus net income a year earlier, alongside completing a buyback of 1,971,454 shares for US$49.4 million and outlining potential milestone inflows tied to zanidatamab and the Theravance Biopharma acquisition.
Management’s emphasis on a US$250 million U.S. approval milestone for zanidatamab, plus further global regulatory payments, highlights a shift toward milestone-driven cash generation even as...